Assess whether a CMO finding is a delay or a refuse-to-file risk (1cff57)

Situation

A mid-size sponsor after a complete response letter cannot treat a DSMB note on an imbalance that is not yet a signal as color commentary on complete-response-letter deficiency list. CMC change-control owner must close a CMO finding is from that extract under Pharma & Life Sciences / Pharmacovigilance.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose A CMO finding is a delay / A refuse-to-file risk using complete-response-letter deficiency list after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• Authorize A CMO finding is a delay now; complete-response-letter deficiency list already has the discriminator after a DSMB note on an imbalance that is not yet a signal.
• Keep A refuse-to-file risk in force until complete-response-letter deficiency list is completed after a DSMB note on an imbalance that is not yet a signal for CMC change-control owner.
• Treat complete-response-letter deficiency list as A CMO finding is a delay because both readings appear after a DSMB note on an imbalance that is not yet a signal.
• Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the page a CMO finding is turns on in complete-response-letter deficiency list.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a DSMB note on an imbalance that is not yet a signal.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• For this Pharma & Life Sciences Pharmacovigilance file, read complete-response-letter deficiency list against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move a CMO finding is for CMC change-control owner.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Pharmacovigilance packet (complete-response-letter deficiency list after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for CMC change-control owner in a mid-size sponsor after a complete response letter.